
First month of SGLT2i use poses highest hypovolemia risk! A study of 1200 patients with type 2 diabetes mellitus found the greatest risk of severe hypovolemia occurred within the first 30 days of treatment (IRR 7.39), peaking between days 22–28 (IRR 15.24). Findings emphasize the need for early monitoring to mitigate dehydration risks.
Like
Save
Share